SoftOx pivots to chronic lung diseases, targeting cystic fibrosis

SoftOx Solutions AS has outlined a strategic shift to focus on chronic lung diseases, specifically Cystic Fibrosis (CF) and Non-Cystic Fibrosis Bronchiectasis (NCFB). This pivot aims to leverage the company's "resistance-proof" antimicrobial therapy (SIS) to combat antibiotic-resistant infections. The company’s solution has demonstrated strong pan-spectrum antimicrobial effects and a favorable safety profile, with no induction of antimicrobial resistance.

The company's Proof of Concept (PoC) study will target CF, a model disease for chronic airway infections, with an addressable market estimated at over $600m. Positive PoC results in CF are expected to open doors for additional studies in NCFB, an even larger addressable market estimated at over $5bn. SoftOx plans a €7-8m investment to conclude Phase IIa and conduct partnership processes, aiming for a PoC readout in H1 2027.

The investor update also addresses financing through a new equity placement facility with Long State Investment, providing up to NOK 80m over 36 months, enhancing financial flexibility for upcoming clinical trials.